NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
CompletedPhase 4
Sponsor: Novartis Pharmaceuticals
Conditions: Primary Hypercholesterolemia, Mixed Dyslipidemia
Interventions: inclisiran
Countries: India
This study is to generate post-marketing safety and effectiveness data of inclisiran sodium in Indian patients as per approved indication i.e., primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia that more closely resembles the real-world population intended to be treated with inclisiran sodium.
Eligibility overview
Sex: ALL
Age: 18 Years to 100 Years
Healthy volunteers: No
Study type: INTERVENTIONAL
Eligibility criteria
Inclusion Criteria: 1. Male and female Indian participants aged ≥18 years or older. 2. Participants for whom the treating physician prescribes treatment with inclisiran sodium in adherence with the India PI i.e., patients who are diagnosed with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia, as an adjunct to diet: 1. in combination with a statin or statin with other LLTs in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or 2. alone or in combination with other LLTs in patients who are intolerant to statins or for whom a statin is contraindicated. 3. Participants on LLTs should be on a stable dose for ≥30 days before the first dose administration of the study treatment. Exclusion Criteria: 1. Any surgical and/or medical condition, which in the opinion of the treating physician, may place the participant at higher risk of his/her participation in the study, or is likely to prevent the participant from complying with the requirements of the study or completing the study. 2. Participants who have previous exposure to inclisiran sodium. 3. Pregnant or nursing (lactating) women.
Locations (9)
- Bangalore, Karnataka, India
- Belagavi, Karnataka, India
- Mumbai, Maharashtra, India
- Nagpur, Maharashtra, India
- New Delhi, National Capital Territory of Delhi, India
- Jaipur, Rajasthan, India
- Madurai, Tamil Nadu, India
- Vellore, Tamil Nadu, India
- Kolkata, West Bengal, India